Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:EYES

Second Sight Medical Products (EYES) Stock Price, News & Analysis

Second Sight Medical Products logo

About Second Sight Medical Products Stock (NASDAQ:EYES)

Key Stats

Today's Range
N/A
50-Day Range
$4.11
$13.05
52-Week Range
N/A
Volume
36,800 shs
Average Volume
132,982 shs
Market Capitalization
$54.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.

Receive EYES Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Second Sight Medical Products and its competitors with MarketBeat's FREE daily newsletter.

EYES Stock News Headlines

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
Q3 2024 GeneDx Holdings Corp Earnings Call
See More Headlines

EYES Stock Analysis - Frequently Asked Questions

Second Sight Medical Products, Inc. (NASDAQ:EYES) released its earnings results on Monday, June, 29th. The medical device company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($1.23) by $0.48.

Shares of Second Sight Medical Products reverse split on the morning of Friday, August 19th 2022. The 1-3 reverse split was announced on Friday, August 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

Second Sight Medical Products (EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Canopy Growth (CGC) and Shopify (SHOP).

Company Calendar

Last Earnings
6/29/2020
Today
11/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical Equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:EYES
Employees
15
Year Founded
N/A

Profitability

Net Income
$-8,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.38 million
Book Value
$4.80 per share

Miscellaneous

Free Float
6,935,000
Market Cap
$54.38 million
Optionable
Optionable
Beta
2.55

Social Links

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:EYES) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners